Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
revised:
29
05
2024
received:
22
02
2024
accepted:
29
05
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
We compared the accuracy of amyloid and [ Participants with FTP-PET, amyloid-PET, and diagnosis of dementia-AD (n = 102), MCI-AD (n = 41), non-AD diseases (n = 76), and controls (n = 20) were included. AD status was determined independent of PET by cerebrospinal fluid or plasma biomarkers. The mean age was 66.9 years, and 44.8% were women. Three readers interpreted scans blindly and independently. Amyloid-PET was classified as positive/negative using tracer-specific criteria. FTP-PET was classified as positive with medial temporal lobe (MTL) binding as the minimum uptake indicating AD tau (tau-MTL+), positive with posterolateral temporal or extratemporal cortical binding in an AD-like pattern (tau-CTX+), or negative. The majority of scan interpretations were used to calculate diagnostic accuracy of visual reads in detecting MCI/dementia with fluid biomarker support for AD (MCI/dementia-AD). Sensitivity of amyloid-PET for MCI/dementia-AD was 95.8% (95% confidence interval 91.1-98.4%), which was comparable to tau-CTX+ 92.3% (86.7-96.1%, p = 0.67) and tau-MTL+ 97.2% (93.0-99.2%, p = 0.27). Specificity of amyloid-PET for biomarker-negative healthy and disease controls was 84.4% (75.5-91.0%), which was like tau-CTX+ 88.5% (80.4-94.1%, p = 0.34), and trended toward being higher than tau-MTL+ 75.0% (65.1-83.3%, p = 0.08). Tau-CTX+ had higher specificity than tau-MTL+ (p = 0.0002), but sensitivity was lower (p = 0.02), driven by decreased sensitivity for MCI-AD (80.5% [65.1-91.2] vs. 95.1% [83.5-99.4], p = 0.03). Amyloid- and tau-PET visual reads have similar sensitivity/specificity for detecting AD in cognitively impaired patients. Visual tau-PET interpretations requiring cortical binding outside MTL increase specificity, but lower sensitivity for MCI-AD. ANN NEUROL 2024.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Vetenskapsrådet
ID : 2022-00775
Organisme : Swedish Alzheimer Foundation
ID : AF-980907
Organisme : Swedish Brain Foundation
ID : FO2021-0293
Organisme : The Parkinson Foundation of Sweden
ID : 1412/22
Organisme : Alzheimer's Association
ID : AACSF-19-617663
Pays : United States
Organisme : Alzheimer's Association
ID : SG-23-1061717
Pays : United States
Organisme : Alzheimer's Association
ID : ZEN-21-848216
Pays : United States
Organisme : Korea Health Technology R&D Project
ID : HU20C0164
Organisme : Swedish Federal Government under the ALF Agreement
ID : 2022-Projekt0080
Organisme : Knut och Alice Wallenbergs Stiftelse
ID : 2017-0383
Organisme : NIA NIH HHS
ID : K23-AG059888
Pays : United States
Organisme : NIA NIH HHS
ID : K23-AG076960
Pays : United States
Organisme : NIA NIH HHS
ID : K99-AG065501
Pays : United States
Organisme : NIA NIH HHS
ID : P01-AG019724
Pays : United States
Organisme : NIA NIH HHS
ID : P30-AG062422
Pays : United States
Organisme : NIA NIH HHS
ID : R01-AG038791
Pays : United States
Organisme : NIA NIH HHS
ID : R35-AG072362
Pays : United States
Organisme : NINDS NIH HHS
ID : R01-NS050915
Pays : United States
Organisme : ERA PerMed
ID : ERAPERMED2021-184
Organisme : Regionalt Forskningsstöd
ID : 2022-1259
Organisme : Skåne University Hospital Foundation
ID : 2020-O000028
Informations de copyright
© 2024 American Neurological Association.
Références
Abner EL, Kryscio RJ, Schmitt FA, et al. Outcomes after diagnosis of mild cognitive impairment in a large autopsy series: outcomes of MCI. Ann Neurol 2017;81:549–559.
Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer disease centers, 2005–2010. J Neuropathol Exp Neurol 2012;71:266–273.
Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis 2023;10:362–377. https://doi.org/10.14283/jpad.2023.30.
Villemagne VL, Doré V, Burnham SC, et al. Imaging tau and amyloid‐β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 2018;14:225–236.
Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta‐analysis. JAMA 2015;313:1924–1938.
Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta‐analysis. JAMA 2015;313:1939–1949.
Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age‐related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014;128:755–766.
Braak H, Braak E. Neuropathological stageing of Alzheimer‐related changes. Acta Neuropathol 1991;82:239–259.
Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol Psychiatry 2019;24:1112–1134.
Schöll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron 2016;89:971–982.
Yoon B, Guo T, Provost K, et al. Abnormal tau in amyloid PET negative individuals. Neurobiol Aging 2022;109:125–134.
Jack CR, Wiste HJ, Weigand SD, et al. Age‐specific and sex‐specific prevalence of cerebral β‐amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross‐sectional study. Lancet Neurol 2017;16:435–444.
Ossenkoppele R, Hansson O. Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. Alzheimers Dement 2021;17:1998–2008.
Baker SL, Harrison TM, Maass A, et al. Effect of off‐target binding on 18F‐Flortaucipir variability in healthy controls across the life span. J Nucl Med 2019;60:1444–1451.
Soleimani‐Meigooni DN, Iaccarino L, La Joie R, et al. 18F‐flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain 2020;143:3477–3494.
Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 2018;320:1151–1162.
Sonni I, Lesman Segev OH, Baker SL, et al. Evaluation of a visual interpretation method for tau‐PET with 18F‐flortaucipir. Alzheimer's Dement: Diagn Assess Dis Monit 2020;12:e12133‐e12144. https://doi.org/10.1002/dad2.12133.
Fleisher AS, Pontecorvo MJ, Devous MD, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease Neuropathologic changes. JAMA Neurol 2020;77:829–839.
Tauvid (Flortaucipir F 18 Injection) [Package Insert]. Philadelphia (PA): Eli Lilly and Company, Avid Radiopharmaceuticals, 2020.
Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 2016;87:375–383.
Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 2022;28:1398–1405.
Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 2021;20:739–752.
Janelidze S, Bali D, Ashton NJ, et al. Head‐to‐head comparison of 10 plasma phospho‐tau assays in prodromal Alzheimer's disease. Brain 2023;146:1592–1601.
Ashton NJ, Puig‐Pijoan A, Milà‐Alomà M, et al. Plasma and CSF biomarkers in a memory clinic: head‐to‐head comparison of phosphorylated tau immunoassays. Alzheimer's Dement 2023;19:1913–1924.
Mattsson‐Carlgren N, Grinberg LT, Boxer A, et al. Cerebrospinal fluid biomarkers in autopsy‐confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 2022;98:e1137–e1150.
Mattsson‐Carlgren N, Andersson E, Janelidze S, et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease. Sci Adv 2020;6:eaaz2387.
Roldán‐Nofuentes JA. Compbdt: an R program to compare two binary diagnostic tests subject to a paired design. BMC Med Res Methodol 2020;20:143.
Gwet KL. Testing the difference of correlated agreement coefficients for statistical significance. Educ Psychol Meas 2016;76:609–637.
Costoya‐Sánchez A, Moscoso A, Silva‐Rodríguez J, et al. Increased medial temporal tau positron emission tomography uptake in the absence of amyloid‐β positivity. JAMA Neurol 2023;80:1051–1061. https://doi.org/10.1001/jamaneurol.2023.2560.
Gomperts SN, Locascio JJ, Makaretz SJ, et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol 2016;73:1334–1341.
Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB. Diagnostic accuracy of 123I‐FP‐CIT (DaTSCAN) in dementia with Lewy bodies: a meta‐analysis of published studies. Parkinsonism Relat Disord 2012;18:225–229.
McCleery J, Morgan S, Bradley KM, et al. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev 2015;1:CD010633.
Quadalti C, Palmqvist S, Hall S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med 2023;29:1964–1970.
Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α‐Synuclein in patients with Synucleinopathies. JAMA 2024;331:1298–1306.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER‐ALZ 2 randomized clinical trial. JAMA 2023;330:512–527.
Zhu X‐C, Tan L, Wang H‐F, et al. Rate of early onset Alzheimer's disease: a systematic review and meta‐analysis. Ann Transl Med 2015;3:38.
Cho H, Mundada NS, Apostolova LG, et al. Amyloid and tau‐PET in early‐onset AD: baseline data from the longitudinal early‐onset Alzheimer's disease study (LEADS). Alzheimer's Dement 2023;19:S98–S114.
Seibyl JP, DuBois JM, Racine A, et al. A visual interpretation algorithm for assessing brain tauopathy with 18F‐MK‐6240 PET. J Nucl Med 2023;64:444–451.
Shuping JL, Matthews DC, Adamczuk K, et al. Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET. Alzheimer's Dement: Transl Res Clin Interventions 2023;9:e12372.
Iaccarino L, La Joie R, Koeppe R, et al. rPOP: robust PET‐only processing of community acquired heterogeneous amyloid‐PET data. Neuroimage 2022;246:118775.